News for CureVac B.V Stock (CVAC)

3 Stocks to Purge ASAP Before They're Pulled off Life Support

InvestorPlace • 05/10/24

CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript

Seeking Alpha • 04/24/24

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Accesswire • 04/24/24

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Accesswire • 04/24/24

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Accesswire • 04/24/24

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Accesswire • 04/18/24

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Accesswire • 04/16/24

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Accesswire • 04/04/24

Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

Zacks Investment Research • 01/26/24

Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

Zacks Investment Research • 01/25/24

CureVac stock gains as COVID vaccine candidates show promise

Market Watch • 01/05/24

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Accesswire • 01/05/24

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Accesswire • 12/19/23

Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?

Zacks Investment Research • 11/21/23

CureVac N.V. (CVAC) Q3 2023 Earnings Call Transcript

Seeking Alpha • 11/14/23

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Accesswire • 11/14/23

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

Accesswire • 11/01/23

Why CureVac Stock Plunged Today

The Motley Fool • 09/29/23

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

Accesswire • 09/28/23

CureVac signals progress on mRNA flu vaccine

Market Watch • 09/12/23

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

Accesswire • 09/12/23

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Accesswire • 08/17/23

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

Accesswire • 08/01/23

CureVac's CVGBM Trial: Promising Results Progress Pipeline

Seeking Alpha • 07/24/23

Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology

Business Wire • 07/21/23